Jubilant Ingrevia Ltd.
601.90
INR
-7.55
(-1.24%)
ISIN
INE0BY001018
Return %
Stock
S&P 500
1Y
-12.12
14.39
3Y
36.27
81.42
5Y
-11.15
68.62
Capital Structure
INR
•
in mil. unless spec.Working Capital
INR
•
in mil. unless spec.Growth Rates
INR
•
in mil. unless spec.Quarterly Revenue
INR
•
in mil. unless spec.Quarterly Earnings Per Share
INR
•
in mil. unless spec.Quarterly Dividends Per Share
INR
•
in mil. unless spec.Company Description
- CEO
- Deepak Jain
- Full Time Employees
- 3,429
- Sector
- Process industries
- Industry
- Chemicals: major diversified
- Address
- 1A, Sector 16A Noida UP India 201301
- IPO Date
- Mar 19, 2021
- Website
- jubilantingrevia.com
- Similar Companies
- Business
- Jubilant Ingrevia Limited is a global integrated life science products and specialty chemicals company headquartered in Noida, India, established in 2020 following the demerger from Jubilant Life Sciences. The company manufactures and supplies a broad portfolio of over 130 products and customized solutions, serving pharmaceutical, nutrition, agrochemical, consumer, and industrial sectors. Its core offerings are organized into three primary business segments: Specialty Chemicals; Nutrition & Health Solutions; and Chemical Intermediates. Key products include bio-pyridine and picolines, fine chemicals, agrochemicals, custom research and manufacturing services (CRAMS), microbial control solutions, piperidines and their derivatives, diketene chemistry products, vitamin B3, B4, choline salts, nutritional premixes, antioxidants, and industrial chemicals such as acetic anhydride, acetic acid, ethyl acetate, and ethanol. Recently, the company announced significant advancements in its growth strategy including the commissioning of a $300 million Agro-Innovator project and ground-breaking of a new multipurpose plant in Gajraula to expand its CDMO (Contract Development and Manufacturing Organization) capabilities, aiming to serve a major CDMO order starting early 2026. Jubilant Ingrevia is also expanding its specialty chemicals and nutrition portfolio, particularly focusing on high-margin product categories and international markets spanning North America, Europe, and Asia. The company pursues cost-efficiency initiatives under its Lean 2.0 program and has entered a renewable energy sourcing collaboration, demonstrating a commitment to sustainability and operational efficiency. Additionally, the company’s Board has declared a significant interim dividend reflecting robust financial performance. The company follows a strategic vision called Pinnacle 345 to achieve triple revenue and quadruple EBITDA within five years through product innovation, capacity expansion, and global market penetration. Jubilant Ingrevia serves global customers with manufacturing facilities and R&D centers leveraging over 35 chemistry and technology platforms. Its Nutrition & Health Solutions segment spans animal and human nutrition with products like feed additives, supplements, and food-grade ingredients, while Specialty Chemicals deliver fine chemicals, building blocks, and agrochemical intermediates. The Chemical Intermediates segment focuses on process development, scale-up, and commercial manufacturing of advanced intermediates for pharmaceuticals and agrochemicals. The company maintains a strong export footprint and invests significantly in sustainability, research and development, and capacity expansion to drive long-term value creation and market leadership in specialty chemicals and life sciences. Jubilant Ingrevia operates with a strategic emphasis on innovation, sustainability, and customized manufacturing solutions, targeting pharmaceutical, nutrition, agrochemical, consumer, and industrial customers worldwide. It has a history rooted in the Jubilant Bhartia Group with over 45 years of chemical industry legacy and remains focused on expanding its global reach, product portfolio, and operational excellence. Its recent investments and projects underscore a commitment to future growth, profitability, and environmental responsibility. This comprehensive profile captures the company’s detailed product range, market presence, strategic initiatives, and recent significant projects and operational developments as of late 2025.